Use of pegylated il-10 to treat cancer

a technology of il-10 and cytokine, which is applied in the field of mammalian cytokine molecules, can solve the problems of relatively short serum half life of il-10, e.g., 2-6 hours, and achieve the effects of inhibiting or reducing tumor growth, improving tumor growth modulator, and improving tumor growth

Inactive Publication Date: 2009-08-27
SCHERING CORP
View PDF7 Cites 33 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

PEG-IL-10 effectively inhibits tumor growth, reduces tumor size, and increases CD8+ T cell infiltration into tumors, providing a sustained therapeutic benefit compared to non-pegylated IL-10, with potential applications in treating various cancers including colon, ovarian, breast, and melanoma.

Problems solved by technology

Excessive immune response can produce pathological consequences, such as autoimmune disorders, whereas impaired immune response may result in cancer.
Unfortunately, the serum half life for IL-10 is relatively short, i.e., 2-6 hours (see, e.g., Smith et al.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

examples

I. General Methods

[0065]Standard methods in molecular biology are described (Maniatis, et al. (1982) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Sambrook and Russell (2001) Molecular Cloning, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Wu (1993) Recombinant DNA, Vol. 217, Academic Press, San Diego, Calif.). Standard methods also appear in Ausubel, et al. (2001) Current Protocols in Molecular Biology, Vols. 1-4, John Wiley and Sons, Inc. New York, N.Y., which describes cloning in bacterial cells and DNA mutagenesis (Vol. 1), cloning in mammalian cells and yeast (Vol. 2), glycoconjugates and protein expression (Vol. 3), and bioinformatics (Vol. 4).

[0066]Methods for protein purification including immunoprecipitation, chromatography, electrophoresis, centrifugation, and crystallization are described (Coligan, et al. (2000) Current Protocols in Protein Science, Vol. 1, John Wiley and Sons, Inc., New Yo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
sizeaaaaaaaaaa
binding compositionsaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

Provided are methods of treatment for tumors. In particular, methods are provided for use of a chemically modified IL-10 to treat tumors.

Description

[0001]This application is a Continuation patent application of U.S. patent application Ser. No. 11 / 862,626 filed Sep. 27, 2007, which claims benefit of U.S. Provisional patent application No. 60 / 915,603, filed May 2, 2007 and claims benefit of U.S. Provisional patent application No. 60 / 848,326, filed Sep. 28, 2006, all of which are hereby incorporated by reference in their entirety.FIELD OF THE INVENTION[0002]The present invention concerns uses of mammalian cytokine molecules and related reagents. More specifically, the invention relates to identification of chemically modified mammalian cytokine proteins that can be used in the treatment of proliferative disorders.BACKGROUND OF THE INVENTION[0003]Cancers and tumors can be controlled or eradicated by the immune system. The immune system includes several types of lymphoid and myeloid cells, e.g., monocytes, macrophages, dendritic cells (DCs), eosinophils, T cells, B cells, and neutrophils. These lymphoid and myeloid cells produce sec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(United States)
IPC IPC(8): A61K38/20A61P35/00
CPCA61K38/2066A61K45/06A61K47/48215A61K47/60A61P1/18A61P11/00A61P13/12A61P15/00A61P35/00A61P35/02A61P35/04A61P43/00A61K47/50A61K39/39558C07K16/30C07K16/3015C07K16/3023C07K16/3046C07K16/3069C07K2317/76
InventorOFT, MARTINSHEPPARD, CATHERINEMUMM, JOHNWU, LINGLING
OwnerSCHERING CORP